Retatrutide 8 mg: Reading the Phase 2 Results
At 48 weeks, the combined 8 mg Phase 2 groups had an estimated mean weight change of −22.8%. The paper also reports results for the placebo group and the other assigned amounts.
At 48 weeks, the combined 8 mg Phase 2 groups had an estimated mean weight change of −22.8%. The paper also reports results for the placebo group and the other assigned amounts.
An estimand specifies the effect a study is trying to estimate. It describes the population, endpoint and handling of events such as discontinuing the assigned treatment.
The sponsor reported 25.9% average weight reduction at 80 weeks in the TRIUMPH-1 9 mg arm under its efficacy analysis, versus 2.2% with placebo.
The retatrutide Phase 2 obesity study designated percentage change in body weight at 24 weeks as its primary endpoint. The frequently cited 48-week weight changes came from later follow-up.
Glucagon receptor activity distinguishes retatrutide’s target profile from that of tirzepatide and semaglutide. Research on the combined profile includes effects on body weight and metabolic measures.
The 12 mg Phase 2 arm had an estimated mean weight reduction of 24.2% at 48 weeks. The sponsor’s TRIUMPH-1 efficacy analysis reported a 28.3% mean reduction at 80 weeks in its 12 mg arm.
A randomized Phase 2a substudy evaluated participants with elevated liver fat. Its main measure was relative change in liver fat at 24 weeks, assessed within a selected group from the obesity study.
The terms single, dual and triple refer to the number of receptor targets. Semaglutide targets GLP-1, tirzepatide targets GLP-1 and GIP, and retatrutide targets GLP-1, GIP and glucagon.
Dose-ranging trials measure whether group-level outcomes change across assigned amounts. Retatrutide Phase 2 results showed a pattern of greater mean weight reduction in higher target groups.
As of November 6, 2026, retatrutide remains investigational in the United States. Published trial findings and regulatory approval are different milestones.